Journal
ONCOIMMUNOLOGY
Volume 6, Issue 12, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1363138
Keywords
immunotherapy; MVA; p53; PD-1; pembrolizumab; triple negative breast cancer; T cell response; vaccine; vaccinia
Categories
Funding
- Hope Portfolio Fund [R21CA114889, NCI-SAIC 25XS061, FAMRI 042275, 2 K12 CA001727]
- Phase One Foundation
- National Cancer Institute of the National Institutes of Health [P30CA033572]
Ask authors/readers for more resources
A heavily pretreated patient with triple negative breast cancer distinguished by cutaneous metastases received p53MVA vaccine in combination with pembrolizumab. Her cutaneous metastases regressed and after 2 cycles of therapy, a skin biopsy showed a complete pathological response. Systemic response was confirmed with restaging CT and bone scans. Activation of p53-specific T cell responses and elevation of multiple immune response genes in peripheral blood correlated with the rapid clinical response which lasted for 6 months after the initiation of combined therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available